Floatz logo

Recombinant Fowlpox-Gm-Csf

Ovarian Endometrioid Adenocarcinoma

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Ovarian Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
University of Colorado, Denver
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Mayo Clinic
Phase 2BB

View all 50 →

Same molecule, other indications

Recombinant Fowlpox-Gm-Csf is also rated in:

prostate neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →
gallbladder adenocarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →